Ena Respiratory is a biotechnology company aiming to transform the treatment and prevention of respiratory infections. The company initial focus is to target respiratory infections in patients with asthma and COPD.
ENA Respiratory Pty Ltd is a clinical-stage pharmaceutical company developing INNA-051, an intranasal innate immune modulator for the prevention of complications associated with respiratory viral infections in at-risk populations, including the elderly, those with chronic lung conditions and individuals with occupational risk (e.g. first responders, military or essential services personnel). The company is also developing its innate immune modulators as vaccine adjuvants.
Based in Melbourne (Australia), the company has secured over AUD35 million Series A investment from Brandon Capital Partners’ managed funds, the Minderoo Foundation and Uniseed.
In 2022, ENA Respiratory partnered with the US-based COPD Foundation to accelerate the clinical development of INNA-051 in COPD through its access to patients, a global network of accredited centres, scientific expertise, and patient investigators.
That year, the company was also the first in the Asia Pacific region to be selected to join BLUE KNIGHT™, a joint initiative between Johnson & Johnson Innovation and U.S. BARDA. In 2023, the company was additionally awarded a USD4.38 million contract from the U.S. Department of Defense to support the ongoing development of INNA-051.
